Clinical Trial Design for Triglyceride-Rich Lipoprotein-Lowering Therapies: JACC Focus Seminar 3/3

Area of Science:

• Cardiovascular Medicine
• Lipid Metabolism
• Pharmacology

Background:

• Triglyceride-rich lipoproteins (TRLs) represent a significant source of residual cardiovascular risk in patients with atherosclerotic cardiovascular disease.
• Previous trials targeting triglyceride (TG) levels have yielded disappointing results in reducing major adverse cardiovascular events (MACE), especially when used alongside statin therapy.
• Limitations in clinical trial design may explain the lack of efficacy observed with earlier TG-lowering strategies.

Purpose of the Study:

• To explore the pathophysiology of TRLs and their role in cardiovascular risk.
• To review the pharmacological effects of emerging TRL-lowering therapies.
• To discuss considerations for optimizing the design of future cardiovascular outcomes trials (CVOTs) focused on TRL reduction.

Main Methods:

• Literature review and synthesis of existing research on TRL pathophysiology.
• Analysis of pharmacological mechanisms of novel TG-lowering agents, including RNA-silencing therapies.
• Discussion of clinical trial design principles relevant to evaluating MACE reduction.

Main Results:

• TRLs are strongly implicated in residual cardiovascular risk, independent of LDL-C levels.
• New RNA-silencing therapies offer a promising approach to significantly reduce TRL levels.
• Past trial failures highlight the need for improved methodologies in evaluating TG-lowering therapies.

Conclusions:

• Targeting TRLs is a critical unmet need for reducing residual cardiovascular risk.
• Advancements in RNA-silencing technology provide novel therapeutic avenues for TRL reduction.
• Future cardiovascular outcomes trials require careful design to definitively link TRL lowering with MACE reduction.